Skip to main
ASMB
ASMB logo

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences Inc is strategically focusing on two innovative therapeutic platforms, primarily targeting the hepatitis B virus (HBV) infection and the restoration of a healthy microbiome, which positions the company within a potentially high-growth market due to ongoing advancements in treatment options. The company's HBV-cure program, which includes the development of novel core protein Allosteric Modulators, is significant as it addresses the critical need for improved patient outcomes in a currently underserved patient population, thereby supporting a promising revenue outlook. Assembly's progress in developing these pioneering treatments could lead to substantial market penetration, with projections suggesting peak sales in the U.S. approaching $4 billion, highlighting the potential for strong financial performance and shareholder value.

Bears say

Assembly Biosciences Inc's primary focus on advancing its hepatitis B virus (HBV) cure program has faced significant challenges, with negative outcomes anticipated from key clinical readouts for its drug candidates, ABI-6250 and ABI-1179/5366. The company's recent trial results indicated only modest virologic responses in treatment subjects, raising concerns about the efficacy of its therapies compared to the control group. These factors contribute to a negative outlook on the stock, as the likelihood of advancing its programs in the clinic appears high-risk amidst the current data.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.